ADHD and PMDD: Premenstrual Worsening of Symptoms

The pattern of ADHD symptoms worsening in the premenstrual phase is one of the most consistent things women with ADHD describe in clinic. The underlying biology involves oestrogen and its effect on dopamine signalling, and for a substantial subgroup the worsening meets criteria for premenstrual dysphoric disorder (PMDD). This article covers what the evidence shows, how the two conditions interact, and how UK treatment is shaped.

What PMDD is

PMDD is recognised in DSM-5-TR as a depressive disorder with a cyclical pattern tied to the menstrual cycle ^[1]. The symptoms appear in the week or two before menstruation, substantially improve within a few days of menstruation starting, and remit until the next cycle. The Royal College of Obstetricians and Gynaecologists Green-top Guideline 48 sets out the UK clinical approach ^[2].

PMDD affects roughly 3 to 8 percent of women of reproductive age in the general population. In women with ADHD, the prevalence is higher.

Why ADHD symptoms worsen premenstrually

The mechanism involves oestrogen. Oestrogen modulates dopamine signalling in the prefrontal cortex and striatum, and dopamine signalling is one of the systems most directly affected in ADHD. As oestrogen drops in the late luteal phase, dopamine signalling drops with it, and ADHD symptoms intensify ^[5].

The clinical pattern that follows is recognisable:

• Worsened focus and task initiation in the week before menstruation
• More pronounced emotional regulation difficulty, irritability, and emotional reactivity
• Worsened sleep
• Worsened impulsivity, including risk of binge eating or impulsive spending
• A clear improvement within a few days of menstruation starting
• A return to baseline that, for women with ADHD, is itself already at the demanding end

For many women with ADHD, this pattern explains a substantial proportion of their cycle-to-cycle variation. For a subgroup whose cyclical mood and physical symptoms meet the DSM-5-TR threshold, the diagnosis is PMDD as well as ADHD ^{[1, 4]}.

How often the two co-occur

The dedicated research on PMDD prevalence in women with ADHD is still emerging. Available studies suggest:

• Cyclical worsening of ADHD symptoms is reported by a substantial majority of women with ADHD; estimates in clinical samples are typically 50 percent or higher
• Full PMDD criteria are met at rates significantly higher than the general population, with some estimates two to three times the baseline
• The pattern is independent of, but compounded by, co-occurring anxiety and depression

The Eisenlohr-Moul et al. 2019 work on reliable PMDD diagnosis emphasises that prospective tracking across at least two cycles is required for the diagnosis ^[4]. Retrospective reports of premenstrual worsening are common in women with ADHD, but they are not the same as a formal PMDD diagnosis.

What this means in practice

A few practical implications:

Track the cycle alongside ADHD treatment

Many women with ADHD describe a "good half of the month" and a "difficult half of the month". Naming the pattern is the first step. Prospective tracking across two to three cycles, even informally, often reveals the shape clearly and helps both the woman and the prescriber understand what is happening.

Medication response can vary across the cycle

ADHD stimulants and non-stimulants can feel less effective in the luteal phase, particularly the late luteal phase. This is part of why women sometimes feel "the medication has stopped working" in specific weeks. The detail is in the medication-stops-working article in the library. Adjustments to dose timing or dose level across the cycle are a specialist conversation; cyclic dosing is not a default option but is occasionally used in specialist practice.

PMDD treatment under RCOG guidance

Where PMDD criteria are met, the standard UK approach applies ^[2]:

• Symptom tracking across at least two cycles to confirm the cyclical pattern
• Lifestyle modifications and cognitive behavioural therapy as first-line
• Combined hormonal contraceptives or SSRIs depending on severity; SSRIs can be taken continuously or only in the luteal phase
• More specialist options (different hormonal approaches, GnRH analogues, and in severe refractory cases, surgical management) where first-line is inadequate

For women already on ADHD medication, the PMDD treatment is added to or sequenced with the ADHD treatment. Most combinations are clinically reasonable; specific interactions are checked by the prescriber.

Co-occurring autism changes the picture

A significant proportion of women with ADHD also have undiagnosed autism, and the PMDD pattern is also over-represented in autistic women. The combined picture in AuDHD often produces a particularly severe luteal-phase deterioration. The autism-and-PMDD article in this library covers that overlap.

Hormonal contraceptive choice matters

Some women with ADHD find that combined hormonal contraceptives reduce cyclical symptom variation and improve overall function. Others find that the hormonal pattern of specific contraceptives worsens mood. This is individual and is a conversation with the prescribing GP or specialist; there is no single right answer.

When the cyclical pattern is the leading edge

For many women, the recognition of severe premenstrual worsening is what brings them to ADHD assessment. The picture is usually:

• Lifelong cyclical pattern that has worsened with age, perimenopause, or a recent change in contraception
• Difficulty across the working month that intensifies in specific weeks
• Anxiety or depression diagnoses that have not fully resolved
• A child or partner being diagnosed with ADHD first

A private adult ADHD assessment for women is a sensible next step in this pattern, and NeuroFX builds the menstrual cycle and PMDD picture into the assessment from the start.

What this means in practice

• The premenstrual worsening of ADHD symptoms is driven by oestrogen's effect on dopamine signalling.
• Most women with ADHD experience cyclical worsening; a substantial subgroup meets criteria for PMDD as well as ADHD.
• Prospective tracking across at least two cycles is required to formally diagnose PMDD.
• ADHD medication can feel less effective in the late luteal phase; this is often the medication and the cycle, not the medication failing.
• Treatment usually addresses both, with PMDD treatment under RCOG Green-top Guideline 48 added to or sequenced with ADHD treatment.

When to speak to a professional

Speak to your GP if you suspect cyclical worsening that meets PMDD criteria, particularly if it has been treated as anxiety or depression without full resolution. Prospective symptom tracking across two cycles is the first practical step before the GP appointment. NeuroFX offers private ADHD assessment for adults with a women's pathway that explicitly considers the cycle, hormonal context and PMDD picture. Seek urgent help via 111, 999 or A&E for any acute mental health crisis, including suicidal thinking that is cyclical (a recognised feature of severe PMDD).

Sources

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association Publishing; 2022.
2. Royal College of Obstetricians and Gynaecologists. Management of Premenstrual Syndrome. Green-top Guideline No. 48. https://www.rcog.org.uk/
3. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
4. Eisenlohr-Moul TA, Schmalenberger KM, Owens SA, et al. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder. Psychological Medicine. 2019;49(10):1717-1729.
5. Quinn PO, Madhoo M. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. Primary Care Companion for CNS Disorders. 2014;16(3):PCC.13r01596.